Activated Recombinant Human Coagulation Factor VII Therapy for Intracranial Hemorrhage in Patients with Hemophilia A or B with Inhibitors

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 28, Iss. 2, 1999-03 ,pp. : 93-98

Karger

Access to resources Recommend Favorite

Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?

By Antovic J. P.   Schulman S.   An S. S. A.   Greenfield R. S.   Blombäck M.  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 64, Iss. 8, 2004-11 ,pp. : 745-752

Informa Healthcare

Access to resources Recommend Favorite

Thrombin Generation in Platelet-Poor Plasma Is Normal in Patients with Hereditary Mucocutaneous Haemorrhages

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 33, Iss. 1, 2003-08 ,pp. : 30-35

Karger

Access to resources Recommend Favorite

The pharmacokinetics of a B‐domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 3, 2015-03 ,pp. : 370-379

John Wiley & Sons Inc

Access to resources Recommend Favorite

Thrombin Generation in Platelet-Rich Plasma as a Tool for the Detection of Hypercoagulability in Young Stroke Patients

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 33, Iss. 1, 2003-08 ,pp. : 52-58

Karger

Access to resources Recommend Favorite